5 managers · $1.0B totalData: SEC EDGAR 13F · 2026Q1
Manager holders · last 4 qtrsⓘ
5
2025Q2 – 2026Q1 · flat QoQ
Total position
$1.0B
Combined value across tracked managers
Net move this quarter
↓ Trimming
Weighted by holders' share change
HolderQ actionValue% of port.Style
Baillie GiffordⓘTrim-5.02%$775M0.79%Long-term growth / Global allocation
Patient CapitalⓘAdd+9.3%$175M6.39%Contrarian growth-value / Time arbitrage
HoskingⓘAdd+52.75%$24M0.86%Contrarian value / Global diversified
MarathonAdd+13.58%$21M0.81%Capital cycle / Contrarian value
Horizon KineticsⓘTrim-3.56%$16M0.18%Contrarian / Real assets
What managers sayⓘ
2026-07-10Patient Capital ManagementBullFinding Patience in... an Early 2000s Hip-Hop Song?Detail →
2026-04-23Patient Capital ManagementBull1Q26 Quarterly WebinarDetail →
2026-04-23Scottish Mortgage (Baillie Gifford)NeutralPrivate Investor Forum 2026: Investing in great growth companiesDetail →
2026-04-09Patient Capital ManagementBull“The Worst Brings Out the Best in Us” - Dr. Edith EgerDetail →
2026-04-08Patient Capital ManagementBull1Q26 Portfolio Activity & AttributionDetail →
2026-01-14Patient Capital ManagementBullThe More Things Change, The More They Stay The SameDetail →
2025-10-10Patient Capital ManagementBull3Q25 Portfolio RecapDetail →
2025-07-11Patient Capital ManagementBullA Gem Cannot Be Polished Without Friction, Nor a Man Perfected Without TrialsDetail →
Earnings Callsⓘ
Q1 2026May 6, 2026
›
Q1 earnings exceeded expectations, driven primarily by a diversified portfolio delivering double-digit growth of 10% in portfolio receipts and 13% in royalty receipts.
Key data: portfolio receipts up 10%, royalty receipts up 13%, ROIC 14.1%.
Business progress: Signed a total of $1 billion in R&D co-funding with J&J and Teva; acquired Ziihera (potential $2B peak sales); daraxonrasib nearly doubled median OS to 13 months in a Phase III pancreatic cancer trial; Myqorzo showed positive results in non-obstructive HCM; pipeline anticipates readouts from Novartis's pelacarsen, among others.
Guidance & outlook: Raised full-year 2026 portfolio receipts guidance to $3.325B–$3.45B; royalty receipts growth of 4%–8%; Q2 expected at $740M–$760M due to the step-rate fee reset.
Risks/highlights: Positive signal — Fitch upgraded the credit rating to BBB; expansion of China and AI teams will unlock long-term growth opportunities.
Q4 FY2025February 11, 2026
›
FinancialsⓘFY2025 · Source: SEC EDGAR 10-K
5y revenue CAGR 1% · latest net margin 32.4%
Revenue$2.38B
Rev. YoY+5.1%
Gross margin—
Net margin32.4%
Net income$0.77B
Free cash flow—
Operating cash flow$2.49B
ROE7.9%
Source: SEC EDGAR company filings (10-K). Foreign issuers (20-F/IFRS) not yet covered.